Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsBreaks – Golden Triangle Ventures Inc. (GTVH) Announces Partnership to Boost Operational Capacity, Sustain Revenue Growth in Logistics Division

Golden Triangle Ventures (OTC: GTVH), a multifaceted consulting company, today announced a strategic partnership between LE Logistics, LLC, its wholly owned subsidiary, and West End Trucking, Inc. The partnership is expected to significantly boost the company’s asset base and operational capacity and set the stage for continued revenue growth and long-term success. Under the partnership, LE Logistics will manage and operate a fleet of 13 trucks and trailers under its own and West End’s licenses. Specifically, LE Logistics will handle all day-to-day logistics operations and create a robust system for fleet management, while West End will ensure compliance with all legal and safety standards. LE Logistics will receive 100% of the income generated by the trucks and trailers, with West End handling factoring services through their established provider.

To view the full press release, visit https://cnw.fm/tgEbg

About Golden Triangle Ventures Inc.

Golden Triangle Ventures is a multifaceted consulting company, which operates as the parent business pursuing ventures in the health, entertainment and technology sectors along with others that provide synergistic value to these three core divisions. The company aims to purchase, acquire and/or joint venture with established entities within these areas of business. The goods and services represented are driven by innovators who have passion and commitment in these marketplaces. The company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. The three points of the Golden Triangle exclusively represent the three sectors in which the company aims to do business. Golden Triangle Ventures is highly focused on acquiring a well-diversified portfolio of companies under one umbrella, which are all managed and owned by the company. An amazing team of professionals supports each division and continues to help Golden Triangle Ventures grow daily. For more information about the company, please visit www.GoldenTriangleInc.com.

NOTE TO INVESTORS: The latest news and updates relating to GTVH are available in the company’s newsroom at https://cnw.fm/GTVH

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Alternative Products Expo Arrives in Atlanta

The Alt Pro Expo, presented by Trinity Hemp, is coming to Atlanta on Oct. 10-12, 2024. Atlanta has a vibrant history with a legacy of smoke-shop culture. The southern city attracts retailers and buyers from neighboring cities, blending seamlessly into the new-age Alternative Products scene. Atlanta offers several recreational options to the attendees of the Expo.

The Alternative Products Expo presents a dynamic platform for learning, exhibitions and collaborations in the Alternative Products industry. It brings together manufacturers, retailers, professionals, consumers, and enthusiasts, showcasing the latest products and services in the counterculture industry.

The Alternative Products Expo in Atlanta will offer unique opportunities to the local community. Alternative product traders can showcase their exhibits to world leaders, distributors, investors, and consumers looking for innovative products. They can set up booths, pitch their business ideas and products, or hold one-on-one conversations with potential investors and buyers.

The alternative product category includes a broad spectrum of herbal products, CBD, derivatives, vape products, energy boosts, mood changes, mushrooms, functional beverages, and dietary supplements, to name a few.

The Expo comes up with lucrative offers, product launches, and show-exclusive prices to the attendees of the Alternative Products Expo. The event is a haven for consumers and investors, as registered buyers and reputed brands showcase their bestsellers and trending innovations at the expo platform. Notable media and marketing partners will provide substantial media coverage and phenomenal social media marketing of the event.

Alternative Products Expo, previously known as USA CBD Expo, has evolved over the years to host one of the finest expos for the counterculture industry. It brings the brightest minds, top industry professionals, and promising newcomers for a memorable lifetime experience.

To learn more, please visit https://cnw.fm/tdQyp

Special Offers plus 50k Event Give Away

If you are flying or driving to one of our upcoming AltProExpo events [Atlanta 2024, Miami 2025, Medellin Colombia 2025] you can claim a free $125 flight voucher for 2 people per company, or one $125 voucher if you are driving 3+ hours.
In addition, you may qualify for a free entry pass plus travel coverage.
If you own any of the following, we will help cover your flight to bring you to our shows:
- Smoke Shop
- Gas Station
- Distributor Chain
- Any business where vape, cannabis, hemp, mushrooms, etc., are sold

For more information, see https://cnw.fm/OK2H5, and YouTube video at https://cnw.fm/B3rGK.

About CannabisNewsWire

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Cannabis Reclassification Unlikely to Happen Until After Elections

A ruling on whether to change cannabis classification to a less dangerous substance in the United States is not expected until after the November election, making it a significant topic in the closely contested presidential race.

Last week, the U.S. Drug Enforcement Administration scheduled a hearing on the proposed changes for Dec. 2, 2024. Given this date, a final decision might not be made until the next presidential administration. Although there’s a chance it could happen before the end of President Biden’s term, marijuana attorney Brian Vicente notes that issuing a decision before Inauguration Day would be a rushed action.

The matter may draw fresh focus to the positions taken by presidential contenders regarding marijuana.

Vice President Kamala Harris has shown support for cannabis decriminalization and expressed disapproval of the drug’s current Schedule 1 listing, where it is classified along with LSD and heroin. Harris’s stance has changed over time, though. She took part in enforcing marijuana laws while serving as California’s attorney general in 2010 and opposed the state’s recreational cannabis legalization.

On the other hand, Donald Trump, the GOP nominee, recently expressed support for a marijuana legalization initiative in Florida, reflecting his growing belief that individuals should not be jailed for cannabis use because it is legal in a majority of states. During his 2016 presidential campaign, Trump supported medical cannabis and suggested that states should decide the legality of cannabis. However, during his term, Jeff Sessions, the then-attorney general, reversed an Obama-era directive that limited federal crackdowns on the cannabis industry in states where it was legal.

Marijuana rescheduling would mark the biggest change to drug policy in the United States in 50 years and might have a significant impact on younger voters. Nonetheless, organizations such as Smart Approaches to Marijuana are against the proposal. Kevin Sabet, president of the organization, contends that insufficient evidence exists to support placing cannabis in the less hazardous schedule 3 category, where it would be placed with drugs such as ketamine.

Sabet stated that the DEA’s decision to hold a hearing was a success in making sure that medical science, not politics, would be the deciding factor. He added that his resistance to the proposal is backed by attorneys general from 18 states.

Rescheduling could enable state-licensed cannabis enterprises to claim federal tax deductions that are presently unavailable to anyone engaged in the trade of schedule I or II substances. Some advocates also hope that rescheduling could push Congress to enact laws that would make it easier for banks to provide services to marijuana businesses. Currently, because of its legal classification, most banks are hesitant to offer financial services to cannabis businesses.

Moreover, rescheduling could also simplify cannabis research, as conducting authorized studies on schedule 1 substances is currently challenging. However, some advocates worry that the debate has become too politicized, with the focus on how rescheduling might impact the industry overshadowing the potential benefits.

All that entities such as Innovative Industrial Properties Inc. (NYSE: IIPR) can do is to wait for the next steps of the rescheduling process to play out so that once the final rule is published, they can determine how the change could impact their business projections.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Cannabis Stocks Retreat as Rescheduling Hearing Slated for December

The U.S. marijuana industry, valued at $32.1 billion, entered Labor Day weekend for the second consecutive year with significant developments regarding the Biden administration’s attempts to change marijuana’s classification. Despite this milestone, the reaction has been one of disappointment rather than celebration, following the recent announcement that a crucial hearing about cannabis rescheduling won’t take place until December. This delay led to frustration and a slight dip in cannabis stock values.

Last year, the industry had a more optimistic outlook during this period as federal health regulators had recommended recognizing cannabis as medicine, a major step forward in marijuana reform. However, this year brings a less favorable situation as Anne Milgram, chief of the U.S. Drug Enforcement Administration (DEA), issued a notice in the Federal Register announcing a Dec. 2, 2024, hearing, signaling that the rescheduling of marijuana is unlikely to occur before 2025. Consequently, cannabis businesses will need to wait a while longer for potential tax relief at the federal level.

Representative Earl Blumenauer, cochair of the Congressional Marijuana Caucus, expressed his dissatisfaction, accusing the DEA of holding up progress on a matter that the White House considers important. On the other hand, some observers, such as Shawn Hauser of the legal firm Vicente, say they expected these kinds of delays and pointed out that a hearing was always a real possibility.

Blumenauer’s disappointment mirrors the sentiments of many in the marijuana industry, including prominent entities such as Green Thumb CEO Ben Kovler, who voiced his frustration on social media. The market responded accordingly, with Green Thumb’s stock dropping by more than 8.5%, while other major cannabis companies, including Curaleaf Holdings, Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) and Verano Holdings, experienced similar declines.

The cannabis community’s disappointment spilled onto social media, with industry leaders and advocates expressing their discontent with President Biden, Milgram and even among themselves. Speculation also arose that a potential Republican presidential win, particularly by Donald Trump, could undo the rescheduling process. However, these are only rumors with no factual backing.

Industry insiders, including lobbyists, lawyers and some marijuana executives argue that the December hearing should not be surprising, emphasizing that the rescheduling process initiated by Biden’s executive order in October 2022 remains on track.

The final rule publication will follow the administrative law judge’s hearing, although no specific timeline is mandated by the Administrative Procedure Act. Barring any extended legal challenges, a final decision could still be made before Biden’s term ends on Jan. 25, 2025.

The specifics of who will participate in the December hearing remain unclear. As the industry prepares its case, experts anticipate a showdown with familiar opponents such as Smart Approaches to Cannabis.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Trump Notes Support for Cannabis Ballot Measure in Florida, Wants Public Smoking Banned

Donald Trump recently stated that he was confident Florida voters would pass the cannabis legalization initiative during the November ballot. He emphasized that since marijuana is already legal in many other states, it is unfair for someone to be prosecuted as a criminal in Florida.

In addition, Trump attacked the status quo regulations, saying they endanger public health, destroy lives and expose individuals to fentanyl-contaminated marijuana. If voters approve the measure, he encouraged lawmakers to take action by passing legislation outlawing marijuana use in public places.

Former Florida GOP chair, Senator Joe Gruters, praised Trump’s support for legalization. He said, “I am extremely proud to have President Trump join us in our effort to end the unnecessary incarcerations and arrests of adults for minor cannabis possession and to provide Floridians with the same freedom to access safe, vetted products that over half of the nation already practices.”

In line with Trump’s position, Gruters has pledged to support legislation that would outlaw marijuana use in public places should voters approve the legalization initiative.

Trump told a news reporter at a press conference in August 2024 that he was increasingly inclined to believe that people should not be criminalized for using cannabis, especially since the substance is becoming legalized nationwide. He suggested that he would soon make public his formal stance on the Florida marijuana ballot initiative.

Roger Stone, a longtime ally and Republican strategist, who resides in Florida and supports the legalization initiative, later commented that if Trump does endorse the measure, it would almost certainly lead to its approval.

Meanwhile, Representative Nancy Mace, who is sponsoring the States Reform Act to federally legalize cannabis, expressed her hope that Trump will support the Biden administration’s effort to reschedule cannabis. She also noted that many GOP lawmakers in Congress have been hesitant to embrace cannabis policy reform due to fear.

In his recent comments, Trump also criticized Vice President Kamala Harris for her record on marijuana prosecutions, claiming that she incarcerated thousands of Black individuals for cannabis-related offenses. Although this characterization of Harris’s record is somewhat exaggerated, it highlights Trump’s evolving stance on cannabis decriminalization and his willingness to leverage the issue in the political arena.

Harris has chosen Minnesota Governor Tim Walz as her running mate. Walz has been a strong advocate for marijuana reform, supporting various legislations in Congress and, as governor, signing a comprehensive marijuana legalization bill into law last year.

Marijuana companies such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) will be watching the presidential campaigns to see whether momentum is created for making serious changes at the federal level with regard to marijuana policy.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Home Depot Internal Memo Indicates Company Will Stop Employee Marijuana Tests

One of the largest employers in the United States, Home Depot, is rewriting its rules regarding employee drug testing. A recent document states that the corporation is discontinuing pre-employment substance testing for the majority of its personnel and will no longer include marijuana in its substance-screening panels.

The revised policies will go into effect on Sept. 1, 2024, as stated in a message from human resources distributed this week. According to the memo, cannabis will no longer be tested on drug panels in the U.S., which includes tests carried out following workplace mishaps or in circumstances where there is a plausible suspicion of impairment.

The memo also clarifies that only external candidates with conditional offers for positions such as corporate security and asset protection will be subject to pre-employment substance testing. The changes, however, have no bearing on federal Department of Transportation employees, who are still subject to the current testing procedures.

News of the policy shift first surfaced on Reddit in the r/HomeDepot forum. A user posted that they had been informed of the new protocol during a morning meeting. The user mentioned that as of Sept. 1, 2024, cannabis would no longer be included in drug tests, even in cases of reasonable suspicion. Additionally, the user noted that drug testing for lift equipment operators would also be discontinued.

The Reddit post quickly garnered attention, with several other users claiming to work at Home Depot confirming that they had heard similar updates at their workplaces.

If the changes are implemented, Home Depot will be among the largest private corporations to do away with cannabis testing for staff members. The corporation has more than 400,000 employees spread across some 2,000 outlets in the United States.

The move by Home Depot is not entirely unprecedented. Amazon, another corporate giant, announced in 2021 that it would no longer test a large number of its workers for cannabis use. Additionally, several states have also enacted laws that restrict or prohibit employee substance testing for cannabis. For instance, new employee protections were implemented in Washington State and California this year.

Employers in California are no longer permitted to inquire about a candidate’s prior cannabis use and cannot penalize employees for lawful use of cannabis outside of work. Meanwhile, Washington State’s law protects employees against discrimination for using legal cannabis before being hired, but it does not shield current employees from facing disciplinary action or termination due to their usage of the drug.

Major cannabis companies such as Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) are probably happy that the vestiges of prohibition in the form of pre-employment drug tests are being peeled away by one company after another. With time, the substance could eventually gain the same status as other substances, such as alcohol.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Mothers in Brazil Take Lead in Advocating for Medical Cannabis for Sick Children

Brazil’s most populated state, Sao Paulo, home to more than 44 million residents, made history by being the first to pass legislation granting free access to CBD. The legislative victory was largely driven by Brazilian mothers who spent a decade campaigning tirelessly to access CBD for their ill children.

Combining CBD with other medications has shown promise for lowering seizures in individuals with severe epilepsy.

One of the mothers who led the campaign was Maria Aparecida Carvalho. At the age of 10, her daughter, Clárian, was diagnosed with severe epilepsy, which can lead to life-threatening complications, including the sudden cessation of lung and heart function.

The medications prescribed to Clárian had significant side effects, even requiring near-dialysis treatment due to poisoning. Clárian’s prolonged seizures caused immense fear and sleepless nights for her parents, who took turns watching over her.

The story of Charlotte Figi, a U.S. youngster who suffered from the same illness and went on to become a global representative of the advantages of CBD therapy, motivated Carvalho to seek CBD as an alternative. She told her husband right away, suggesting they look into getting it, even from unofficial sources if needed.

However, a few months later, the neurologist treating Clárian succeeded in smuggling some CBD into the nation by bringing it back from overseas. Eventually, with legal assistance, Carvalho obtained a court permit to cultivate cannabis in her compound, allowing her to produce CBD for her daughter and other patients.

Brazil’s current laws permit marijuana use and its extracts for medical and scientific purposes. However, cultivating it remains illegal, forcing the sector to rely on imported marijuana oil and other raw materials, which significantly drives up costs.

San Paulo state legislator Caio França, a center-leftist, drafted a measure in 2019 that would have allowed families to obtain CBD via the country’s public health system. He lobbied his largely conservative colleagues for three years, gradually winning them over with testimonies from families whose children required CBD for treatment.

The measure passed in 2022 with almost two-thirds approval from the state legislature, and Governor Tarcísio de Freitas, a former member of far-right former President Jair Bolsonaro’s Cabinet, signed it into law in January 2023. Due to his conservative background, de Freitas limited the law’s scope to patients with three rare conditions, including Lennox-Gastaut and Dravet syndromes, based on research showing that CBD was effective for these specific ailments.

For companies that have for long manufactured medical marijuana products, such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED), the stories coming out of Brazil about the ways in which cannabis products are helping mothers to manage the conditions of their ill kids serve as case studies of how cannabinoids can manage symptoms that conventional treatments have been ineffective in combating.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Yields “Extremely Interesting” Results for DehydraTECH(TM) Liraglutide in Ongoing Diabetes Animal Study

Lexaria, a global innovator in drug delivery platforms, has just announced its 4-week and 8-week blood glucose results from its WEIGHT-A24-1 animal study
Two formulations from the study posted outstanding performance, with each utilizing the company’s patented DehydraTECH(TM) technology
DehydraTECH-liraglutide (Group H) and two DehydraTECH-CBD formulations (Groups A & B) posted blood sugar level reductions of 2.50%, 1.90%, and 1.53%, respectively
These results build on the positive results from Lexaria’s 2023 DIAB-A22-1 animal study, which showed a 16.7% blood sugar concentration increase relative to baseline by day 56 for the obese control group that got no treatment

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its 4-week and 8-week blood glucose results from its WEIGHT-A24-1 animal study (the “study”). This study will examine diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and DehydraTECH-processed cannabidiol, alone and in combination . The ongoing study uses diabetic, pre-conditioned Zucker rats, falling in one of three study arms, with dosing lasting 12 weeks (https://cnw.fm/1u3Rj).

Two formulations posted outstanding performance from the study as of day 56 – DehydraTECH-liraglutide (Group H) and two DehydraTECH-CBD formulations (Groups A & B). Most notably, they each posted blood sugar level reductions of 2.50%, 1.90%, and 1.53% respectively. DehydraTECH-liraglutide specifically saw a -2.08% change as of day 28 and a -2.50% change as of day 56 in what Lexaria’s management described as “extremely interesting.”

For Lexaria, these results build on the positive results from its 2023 DIAB-A22-1 animal study, which showed a 16.7% blood sugar concentration increase relative to baseline by day 56 for the obese control group that received no treatment. For the current study, each of the eight active groups of animals either experienced a smaller increase or an actual decrease in blood sugar level relative to baseline compared to the obese control group in the previous study.

The ongoing study featured eight groups. Groups A through D were administered with different DehydraTECH-CBD compositions. Groups E and F utilized reformulated Rybelsus DehydraTECH compositions, whereas groups G and G used pure glucagon-like peptide-1 (“GLP-1”) drugs semaglutide and liraglutide respectively in DehydraTECH compositions. Additional results from this study are expected soon. However, Lexaria’s management remains optimistic that it will replicate both the interim and previous results, ultimately demonstrating the superiority of its DehydraTECH technology.

The global diabetes treatment market was valued at $79.25 billion in 2023. It is projected that by 2032, it will have surpassed $153 billion in valuation, mainly influenced by the growing prevalence of the condition and the increasing demand for effective drug therapies (https://cnw.fm/WhvWz). For the longest time, treatment options have involved painful injections, which, to many, have been a source of discomfort and, to some, an outright deterrent. Lexaria looks to carve out a piece of the diabetes treatment market share by offering an oral alternative and is banking on its DehydraTECH technology to achieve that. Its previous and ongoing studies are a testament to its commitment to this goal and its pledge to creating shareholder value.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (“CBDW”) is a specialized communications platform with a focus on CBD related news and updates in the cannabidiol (“CBD”) sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled recognition and brand awareness.

CBDW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CBDWire, text “CBDWire” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer

CBDWire
Denver, CO
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is powered by IBN

420 with CNW — Could Marijuana Reclassification Be Answer to Maintaining Medicare?

The U.S. Justice Department took significant steps toward changing the legal status of cannabis in May by beginning the process to move the substance from schedule 1 to schedule 3, a less-restrictive category under federal drug laws. This shift is noteworthy because it reflects the recommendations of medical experts at the U.S. Department of Health and Human Services (HHS), who have recognized that cannabis now has an accepted medical use. Equally crucial is that reclassifying marijuana could boost much-needed research into its medical potential.

However, simply changing the plant’s classification won’t be enough to make a substantial impact. True progress will only occur if policymakers take swift and decisive actions to enable more in-depth research into medical marijuana and its potential as an alternative treatment, especially for age-related health issues.

One of the leading proponents of incorporating marijuana-based treatments into elder healthcare is Howard Kessler, creator of the Commonwealth Project in Massachusetts. Kessler played a key role in starting research at the Florida-based MorseLife Health System that discovered more than 62% of senior citizens between the ages of 65 and 75 could cut back on or completely stop taking their prescription drugs by using cannabinoid-based therapy.

Kessler notes that while the findings are encouraging, more extensive research is essential. This kind of research would give seniors and medical professionals the knowledge they need to make educated decisions regarding the advantages of medical marijuana.

Kessler’s advocacy reflects the same commitment that inspired President Lyndon B. Johnson to sign the Medicare and Medicaid Act into law in 1965, creating Medicare to guarantee healthcare coverage for those 65 years of age and older.

Nearly six decades later, this commitment is under strain due to the rising costs of maintaining Medicare. One of the most pressing threats to senior health today is the overreliance on prescribed opioids for pain management. The widespread use of these highly addictive drugs among seniors has led to increased risks of overdose and addiction. In this context, medical marijuana presents a potential alternative.

Evidence from states where cannabis is legal suggests that doctors prescribe significantly fewer doses of painkillers to patients enrolled in Medicare. Based on these figures, medical cannabis might save up to $500 million a year in costs if it were legalized nationwide.

If cannabis is indeed reclassified, conducting more studies to investigate its safe and controlled application in the treatment of pain and other ailments should come first, especially in the context of Medicare Advantage. Such research could not only lead to substantial savings for the Medicare system but also improve the quality of life for seniors by offering them better, safer treatment options.

As entities such as Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) continue to bring to market more efficacious medical-marijuana formulations, the uptake of these treatments could spur additional reforms that could see the existing restrictions further eased.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — NIH Study Finds Concurrent Use of Tobacco, Marijuana Is Rising

The proportion of Americans who use both tobacco and marijuana has been gradually increasing, particularly among older persons, according to a recent study. After analyzing national data spanning 20 years, Duke University School of Medicine researchers caution that combining both drugs can increase the risk to one’s health when compared to using either drug alone.

A reported 6.38% of American adults in 2021 reported using tobacco and marijuana together within the previous month. While this proportion might not seem like much, it is a considerable rise over prior years. The researchers credit this increase to the growing legalization of marijuana in a number of states, which has increased social acceptance and familiarity with cannabis use.

Lead author of the study, Dana Rubenstein, a Duke University researcher and fourth-year medical student, pointed out that the data from 2021 indicates some groups are more likely to utilize both drugs. Co-using tobacco and cannabis was more common among younger adults, those with less education and residents of states that legalized medical cannabis.

Prior research analyzing the patterns of tobacco and cannabis use, separately or in combination, concentrated on data from 2003 to 2012. But in the intervening period, marijuana laws have been relaxed in 24 more states. Most Americans now reside in places where marijuana use for recreational purposes is legal.

The study reviewed data from 708,891 adults surveyed between 2002 and 2021 through the National Survey on Drug Use and Health. Key findings showed that the co-use of tobacco and marijuana steadily rose between 2002 and 2019. Exclusive marijuana use began increasing after 2007, while tobacco use on its own declined during that period.

Interestingly, while most demographic groups experienced an increase in co-use of these substances, young individuals (18 to 25 years of age) went against this trend, with co-use rates falling after 2014. Rubenstein suggests this decline may be due to fewer young adults choosing to use tobacco over the past 20 years.

In contrast, older adults have shown the opposite pattern, with a notable rise in co-use. The most striking increase was observed among adults aged 50 years and above, where co-use jumped from just 0.42% in 2002 to 3.1% in 2019. Among those aged between 26 and 34, the co-use rate nearly doubled from 6.15% to 10.3%. Similarly, those aged between 35 and 49 saw a stable period between 2002 and 2009, followed by a significant uptick, reaching 6.6% in 2019.

The coauthors of the study, Drs. Lauren R. Pacek and F. Joseph McClernon, who were both formerly employed by Duke University, emphasize the significance of developing focused programs to help individuals stop using both drugs. They also note how important it is to distinguish between the purposes of marijuana use — whether they be recreational or medical — and how this affects co-use with tobacco products.

Leading marijuana companies such as Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) are likely to delve deeper into the findings of this study in order to tease out any insights that could be beneficial as the companies make strategic plans for the future.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com